Oruka Therapeutics, Inc.
Company Stats
- Market Cap
- $5.5B
- as of Sep 30, 2026
- Shares Outstanding
- 66.2M
- Free Float
- 49.8%
Income Statement
- Operating Income
- -$122.1M
- Net Income
- -$105.4M
- EBITDA
- -$122.0M
Cash Flow
- Free Cash Flow
- -$88.4M
- FCF Yield
- -1.6%
- Owner FCF Yield
- -2.0%
Balance Sheet
- Cash & Equivalents
- $46.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$88.4M | — |
| FY2024 | — | -$58.0M | — |
| FY2023 | $0 | -$5.0M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 25, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back
Utilities Lead Quarterly Dilution as Materials Buybacks Gain